













Title: Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in 
Oncology: A Systematic Review with a Meta-Analysis 
 
Author: Karolina Strzebońska, Mateusz T. Wasylewski, Łucja Zaborowska, 
Mateusz Blukacz i in. 
 
Citation style: Strzebońska Karolina, Wasylewski Mateusz T., Zaborowska Łucja, 
Blukacz Mateusz i in. (2021). Risk and Benefit for Targeted Therapy Agents in 
Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. 





Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials 
in Oncology: A Systematic Review with a Meta‑Analysis
Karolina Strzebonska1  · Mateusz T. Wasylewski1  · Lucja Zaborowska1  · Maciej Polak1,2  · Emilia Slugocka1  · 
Jakub Stras1  · Mateusz Blukacz3  · Bishal Gyawali4  · Marcin Waligora1 
Accepted: 27 May 2021 
© The Author(s) 2021
Abstract
Background For research with human participants to be ethical, risk must be in a favorable balance with potential benefits. 
Little is known about the risk/benefit ratio for pediatric cancer phase II trials testing targeted therapies.
Objective Our aim was to conduct a systematic review of preliminary efficacy and safety profiles of phase II targeted therapy 
clinical trials in pediatric oncology.
Methods Our protocol was prospectively registered in PROSPERO (CRD42020146491). We searched EMBASE and Pub-
Med for phase II pediatric cancer trials testing targeted agents. We included solid and hematological malignancy studies 
published between 1 January, 2015 and 27 February, 2020. We measured risk using drug-related grade 3 or higher adverse 
events, and benefit by response rates. When possible, data were meta-analyzed. All statistical tests were two-sided.
Results We identified 34 clinical trials (1202 patients) that met our eligibility criteria. The pooled overall response rate was 
24.4% (95% confidence interval [CI] 14.5–34.2) and was lower in solid tumors, 6.4% (95% CI 3.2–9.6), compared with hema-
tological malignancies, 55.1% (95% CI 35.9–74.3); p < 0.001. The overall fatal drug-related (grade 5) adverse event rate was 
1.6% (95% CI 0.6–2.5), and the average drug-related grade 3/4 adverse event rate per person was 0.66 (95% CI 0.55–0.78).
Conclusions We provide an estimate for the risks and benefits of participation in pediatric phase II cancer trials. These data 
may be used as an empirical basis for informed communication about benefits and burdens in pediatric oncology research.
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1 Introduction
Although death rates for cancers have declined by about 50% 
from the 1970s, cancer continues to be one of the leading 
causes of death in the pediatric population [1]. Globally, 
it is estimated that there will be 13.7 million new pediat-
ric cancer cases by 2050 [2]. Hence, new therapeutics that 
meaningfully improve outcomes in pediatric cancers are 
needed [3, 4].
However, pediatric research on anticancer agents poses 
more challenges than research involving adult participants 
[5–7]. Children are considered a vulnerable population, 
thus their enhanced protection is required [8]. Despite chal-
lenges and strict requirements, conducting clinical trials in 
this population is indispensable to confirm the efficacy of 
tested drugs and to protect children against possible negative 
effects of prescribing medications off-label [5, 9, 10].
Cancer phase II studies are an important element of the 
drug development process designed to establish the short-
term activity of new treatments, further evaluate safety and 
toxicity and, if these treatments are sufficiently promising, 
advance them for evaluation in phase III trials [11]. To be 
considered as ethical, research involving pediatric partici-
pants must meet, among others, a favorable risk/benefit ratio 
criterion [12–14]. The determination of whether risks and 
potential benefits of research interventions are acceptable 
requires ethical and clinical expertise and scientific knowl-
edge and data [15]. Numerous studies have considered 
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Key Points 
We conducted a systematic review of activity and safety 
profiles of phase II targeted therapy clinical trials in 
pediatric oncology.
The pooled overall response rate was 24.4%. The average 
drug-related grade 3/4 adverse event rate per person was 
0.66. The overall drug-related fatal (grade 5) adverse 
event rate was 1.6%.
These estimates of risks and benefits are helpful to make 
an informed decision about participation in phase II 
pediatric oncology trials testing targeted therapies.
(KS, MTW) for additional publications on ClinicalTrials.
gov and/or Google Scholar on 3 July, 2020. For a detailed 
description of the search methodology, see the ESM.
2.2  Study Selection and Eligibility Criteria
Five researchers (LZ, MTW, KS, ES, MB) performed title 
and abstract screening for initial study inclusion and four 
researchers (LZ, MTW, ES, JS) performed full-text screen-
ing to determine the final list of included studies. The study 
selection process was conducted independently by two 
researchers, any disagreements were resolved by discussion, 
and when necessary an arbiter was involved (MW, BG).
We included pediatric cancer phase II clinical trials that 
published their results in the last 5 years as well as phase I/II 
or phase II/III studies (if phase II results were reported sepa-
rately) investigating targeted therapy agents. Key inclusion 
criteria were as follows: (1) all or a majority of participants 
(over 50%) were under 21 years old and/or the study was 
indicated as pediatric, or results were provided separately 
for the pediatric population; (2) diagnosis of any malignancy 
(solid or hematological); and (3) assessment of toxicity and/
or response of targeted therapy or a combination of targeted 
therapies (monoclonal antibodies or small molecules or anti-
body drug conjugates [29]). We excluded studies evaluat-
ing: (1) chemotherapy and immunotherapy regimens, or a 
combination of these with targeted therapy; (2) topical only 
or regionally administered drugs (i.e., delivered directly to 
the tumor without any systemic effects); (3) non-pharmaco-
logical modalities (e.g., surgery, radiotherapy, gene therapy, 
stem cell therapy, or any of these combined with targeted 
therapy); or (4) supportive care without anticancer agents or 
with other interventions not falling under a targeted therapy 
category (e.g., antiviral agents). Inclusion and exclusion cri-
teria were defined prospectively in the protocol [27].
2.3  Data Extraction
We created and piloted a data extraction form. On the basis 
of the pilot, we refined and prepared the final version (avail-
able from https:// osf. io/ m7fw3/). Data were extracted from 
each publication and/or ClinicalTrials.gov study record 
independently by two reviewers (LZ, MTW, ES, JS). All 
reviewers received training prior to extraction. Disagree-
ments were resolved by discussion, and when necessary, a 
third person, an arbiter, was involved (MW). An experienced 
medical oncologist had a supervisory role (BG). In the case 
of multiple publications for the same study, the results from 
the full publication and/or the most recent version were used 
in the extraction.
From each study, we extracted data related to: study char-
acteristics (e.g., year of results publication, phase, funding, 
study status), patient characteristics (e.g., age, number of 
adverse events (AEs) and response rates of anticancer agents 
in phase I adults as well as pediatric clinical trials [16–20]; 
others focused on the risks and benefits of particular drugs 
[21, 22] or interventions in specific cancer types [23, 24]. 
Historically, targeted drugs are considered to have a better 
toxicity profile than chemotherapy agents [25, 26]. Yet, little 
is known about the risk-benefit profile for pediatric phase II 
oncology trials of targeted drugs. We conducted a systematic 
review and meta-analysis to systematically assess the risks 
and benefits for pediatric participants in contemporary phase 
II oncology clinical trials testing targeted therapies.
2  Methods
The study protocol was prospectively registered in PROS-
PERO (CRD42020146491) [27]. We followed the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses 
guidelines.
2.1  Search Strategy
We systematically searched PubMed and EMBASE for rel-
evant articles and abstracts published between 1 January, 
2015 and 27 February, 2020, using strategies that included 
keywords and suggested MeSH and Emtree entry terms, 
their synonyms, and closely related words (Table 1 of the 
Electronic Supplementary Material [ESM]). Searches were 
not limited by language. Our search strategies were checked 
using the Canadian Agency for Drugs and Technologies in 
Health peer-review checklist for search strategies [28].
We performed a complementary search of ClinicalTrials.
gov on 23 June, 2020 to find pediatric oncology studies with 
posted results (LZ, MTW). Then, all studies with registration 
numbers were searched by two researchers independently 
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enrolled and eligible participants, type of malignancy), inter-
vention (e.g., number and names of investigated drugs), and 
outcomes (e.g., toxicity, response). For more details, see our 
extraction form (https:// osf. io/ m7fw3/).
2.4  Data Curation
Phase II studies do not generally measure survival end-
points; thus, we decided to use the objective response rate 
as a proxy for the therapeutic benefit [30]. For solid tumor 
studies, we defined benefit as the proportion of participants 
with partial and/or complete response (reported separately 
or as an objective response rate) as defined by study authors. 
To measure benefit for hematological malignancy studies 
(except for acute leukemias and chronic myeloid leukemia), 
we considered any of the various methods of measuring 
partial and/or complete response (e.g., cytogenetic, hema-
tologic, or molecular). For acute leukemias and chronic 
myeloid leukemia, we did not count any types of partial 
responses in our assessment of benefit because anything 
short of a complete response is not considered a benefit for 
these malignancies [31, 32].
We defined risk as the proportion of participants experi-
encing grade 3, 4, or 5 drug-related AEs as defined by the 
Common Toxicity Criteria for Adverse Events, Version 5.0 
(and earlier versions) [33]. An AE was considered as related 
to the study drug if it was clearly stated by the study authors; 
expressions such as “AEs at least possibly related to study 
therapy”, “treatment-emergent AEs”, and “AEs suspected 
to be drug related” were also acceptable. In cases where a 
fatal event was not clearly described as treatment related, we 
excluded it from our drug-related grade 5 AE rate estima-
tions. All data on AEs in our analysis are treatment related. 
To compare the risks and benefits, we analyzed a cohort of 
studies where both drug-related deaths (grade 5 AEs) and 
responses were clearly reported.
2.5  Statistical Analysis
Pooled response rate, treatment-related fatal (grade 5) AE 
rate, and treatment-related grade 3/4 AEs rate were calcu-
lated within each stratum when more than one study pro-
vided data using meta-analytic methods. Modeling with ran-
dom effects and the restricted maximum likelihood estimator 
were used to account for between-study heterogeneity. I2 sta-
tistics were calculated to provide a measure of the proportion 
of overall variation attributable to between-study heteroge-
neity. Differences in response rates between the categories of 
study definition, number of drugs, and the number of types 
of malignancies were assessed using the Q test for hetero-
geneity in meta-regression. Pooled response was calculated 
for categories of publication year (2015–16, 2017–18, and 
2019–20) to assess changes over time. P-values for trends 
in response between 2015 and 2020 were obtained from a 
meta-regression. A meta-analysis was conducted using the 
metafor package (R, Version 3.2.3); p < 0.05 was consid-
ered statistically significant. All tests were two-sided. The 
average number of treatment-related grade 3 and 4 AEs per 
person with a 95% confidence interval (CI) was estimated 
using a Poisson regression model.
2.6  Analysis of Both Solid Tumor and Hematological 
Malignancy Studies
Because large differences were observed in responses 
between solid tumors and hematological malignancies, we 
stratified our analyses by the type of cancer. For three stud-
ies that included both solid and hematological malignancies, 
patients were separated for response data and, for one study 
including both these cancer types, we separated data on the 
drug-related fatal (grade 5) AE rate. The data separation did 
not influence response rates or drug-related fatal (grade 5) 
AEs rates in our analysis.
2.7  Risk of Bias Assessment
Two authors (LZ, MTW) independently assessed the risk of 
bias for all included studies using the Cochrane risk of bias 
tools for randomized or non-randomized studies [34, 35]. 
Judgments were based on the algorithms proposed by the 
authors of ROBINS and RoB2 tools, adjusted to fit the spe-
cific aspects of our analysis. Disagreements were resolved 
by discussion.
3  Results
3.1  Clinical Trial and Patient Characteristics
Our search identified 8317 references and 7375 remained 
after the removal of duplicates. We selected 119 full texts for 
review, of which 31 (concerning 25 clinical trials) met our 
inclusion criteria. After additional searches on ClinicalTri-
als.gov and Google Scholar, we included a total of 34 unique 
clinical trials for extraction (Fig. 1 of the ESM). The list of 
included studies with malignancy names and agents tested 
is presented in Table 2 of the ESM.
Among the 34 clinical trials (N = 1202) included, the 
majority (28; 82.4%) were phase II trials, five (14.7%) 
reported results of a phase I/II trial, and one (2.9%) reported 
a phase II/III trial (Table 1). Twenty-seven trials (79.4%) 
enrolled only pediatric patients, and seven (20.6%) enrolled 
both children and adults. Twenty-two studies (64.7%) 
involved only patients with solid tumors, while nine stud-
ies (26.5%) involved only patients with hematological 
malignancies. The vast majority of trials (31; 91.2%) tested 
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monotherapies and three (8.8%) tested combinations of two 
targeted agents. Twelve studies (35.4%) recommended fur-
ther drug evaluations, and three (8.8%) were against further 
testing. Ten trials (29.4%) were funded by private sponsors, 
11 (32.4%) by public institutions, and 12 (35.3%) by both 
private and public sponsors. The majority of the trials (27; 
79.4%) were conducted in North America.
In 25 studies, the median age of participants was below 
18 years, in three studies, the median age was between 18 
and 21 years, and in the remaining six studies, the median 
age was not reported (Table 2). Twenty-one studies used the 
Lansky/Karnofsky performance scale, two studies used the 
Eastern Cooperative Oncology Group/World Health Organi-
zation/Zubrod scale, and seven studies used both these scales 
to measure performance status for eligibility.
3.2  Benefit
We analyzed 360 responses reported among 1202 par-
ticipants enrolled in 34 clinical trials. The pooled overall 
response rate across all malignancies was 24.4% (95% CI 
14.5–34.2; I2 = 98.5%) (Table 3). The response rate for solid 
tumors among 670 patients was 6.4% (95% CI 3.2–9.6), 
while the response rate for hematological malignancies 
among 522 patients was significantly higher: 55.1% (95% 
CI 35.9–74.3); p < 0.001.
We did not find a significant difference in response rates 
by the type of trial (Table 3 of the ESM). The response rate 
in phase II/III trials vs phase I/II trials vs phase II trials was: 
40.4% (N = 1) vs 33.4% (N = 6) vs 22.2% (N = 30); p = 
0.62. The response rate in seamless phase I/II trials vs phase 
II trials in solid tumors was: 10.5% vs 3.6%; p = 0.08.
We observed higher responses related to the smaller 
number of types of malignancies included in a study. The 
response rate was higher in all trials where three or fewer 
types of malignancies were treated (30.3%) in comparison 
to the trials with four or more types of cancers (2.3%); p = 
0.047.
The comparison of response rates between single-drug 
and multiple-drug studies was not possible because only 
three solid tumor studies investigated two drugs per study. 
In these three studies, none of the participants responded to 
the study drugs.
3.3  Trends in Response Rate
We did not find significant linear time trends in response 
rates (p = 0.96 for hematological malignancies, p = 0.27 for 
solid tumors, p = 0.1 for both hematological malignancies 
and solid tumors) (Fig. 1). The response rate for studies pub-
lished between 2015 and 2016 was 9.2% (95% CI 3.2–15.1), 
and the response rate for trials published in 2017 or 2018 
was 32.3% (95% CI 16.4–48.2).
3.4  Risk
Twenty of the 34 trials reported drug-related fatal (grade 5) 
AEs. There were 16 drug-related grade 5 AEs among 694 
patients, and the overall treatment-related grade 5 AE rate 
was 1.6% (95% CI 0.6–2.5%, I2 = 5.1%) (Table 3). The dif-
ference in the drug-related grade 5 AE rate between solid 
tumors and hematological malignancies was not statistically 
significant (2.5% vs 0.8%; p = 0.1).
One hundred and forty-nine patients (49.0%; 95% CI 
31.3–66.7) experienced treatment-related grade 3/4 AEs in 
12 trials (Table 3). There was no significant difference in the 
occurrence of drug-related grade 3/4 AEs between patients 
with solid tumors (49.2%) and patients with hematological 
malignancies (48.3%); p = 0.81.
One hundred and thirty-one drug-related grade 3/4 AEs 
were reported in eight studies among 199 patients with solid 
tumors, with an average rate per person of 0.66 (95% CI 
0.55–0.78). There were no hematological studies reporting 
drug-related grade 3/4 AEs.
3.5  Direct Comparison of Risk and Benefit
We identified 20 studies where both response rates and drug-
related deaths (grade 5 AEs) were clearly reported (Table 3). 
The response rate was significantly higher in hematological 
studies (36.0%; 95% CI 8.1–64.2) than in solid tumor stud-
ies (2.2%; 95% CI 0.8–3.5); p < 0.01. As described above, 
the treatment-related grade 5 AE rate was 0.8% in hemato-
logical studies and 2.5% in solid tumor trials. We found that 
the response rate was significantly lower in studies report-
ing drug-related grade 5 AEs than in the remaining studies 
lacking data on drug-related grade 5 AEs: 16.0% (95% CI 
6.0–26.0) vs 39.1% (95% CI 21.5–56.7); p = 0.009.
3.6  Risk of Bias Assessment
The risk of bias of the included studies is available on 
https:// osf. io/ vcshp/. There was only one open-label rand-
omized study with the overall risk of bias judgment of ‘some 
concerns’ mainly owing to some differences in the measure-
ment of the outcome between two groups. Among 33 non-
randomized studies, two of them were assessed as having a 
critical risk of bias. The missing data were the major factor 
contributing to high levels of bias marked as “critical” or 
“serious”.
4  Discussion
To our knowledge, we report the first systematic review of 
the risks and benefits of pediatric phase II cancer trials in 
the era of targeted therapy. Our findings suggest that, on 
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Table 1  Characteristics of 34 included clinical trials
Data given as number of studies (%)
a Percentage was calculated by subtracting the remaining % values from 100%
b Some of the studies were conducted in more than 1 location
Characteristic Category Type of tumor Total
Solid Hematological Both
All studies 22 (64.7) 9 (26.5) 3 (8.8) 34 (100)
Publication year 2015 7 (31.8) 1 (11.1) 0 (0) 8 (23.5)
2016 5 (22.7) 0 (0) 1 (33.3) 6 (17.7)
2017 2 (9.1) 3 (33.4a) 2 (66.7) 7 (20.6)
2018 5 (22.7) 4 (44.4) 0 (0) 9 (26.5)
2019 2 (9.1) 1 (11.1) 0 (0) 3 (8.8)
2020 1 (4.6) 0 (0) 0 (0) 1 (2.9)
Locationsb Africa 0 (0) 1 (11.1) 0 (0) 1 (2.9)
Asia 0 (0) 3 (33.3) 0 (0) 3 (8.8)
Australia 4 (18.2) 3 (33.3) 0 (0) 7 (20.6)
Europe 8 (36.4) 5 (55.6) 1 (33.3) 14 (41.2)
North America 17 (77.3) 8 (88.9) 2 (66.7) 27 (79.4)
South America 1 (4.6) 1 (11.1) 0 (0) 2 (5.9)
Not reported 1 (4.6) 0 (0) 0 (0) 1 (2.9)
Funding Private 6 (27.2a) 4 (44.4) 0 (0) 10 (29.4)
Public 10 (45.5) 1 (11.2a) 0 (0) 11 (32.4)
Mixed 5 (22.7) 4 (44.4) 3 (100) 12 (35.3)
Unclear 1 (4.6) 0 (0) 0 (0) 1 (2.9)
Study status Active, not recruiting 3 (13.6) 4 (44.4) 1 (33.3) 8 (23.5)
Completed 13 (59.1) 4 (44.4) 2 (66.7) 19 (55.9)
Terminated 4 (18.2) 1 (11.2a) 0 (0) 5 (14.7)
Not reported 2 (9.1) 0 (0) 0 (0) 2 (5.9)
Study definition Phase I/II 3 (13.6) 1 (11.1) 1 (33.3) 5 (14.7)
Phase II 19 (86.4) 7 (77.8) 2 (66.7) 28 (82.4)
Phase II/III 0 (0) 1 (11.1) 0 (0) 1 (2.9)
Population Pediatric only 16 (72.7) 8 (88.9) 3 (100) 27 (79.4)
Mixed 6 (27.3) 1 (11.1) 0 (0) 7 (20.6)
Number of tumor types studied in the trial 1 type 10 (45.5) 7 (77.8) 0 (0) 17 (50.0)
2 or 3 types 5 (22.7) 2 (22.2) 1 (33.3) 8 (23.5)
4 types 2 (9.1) 0 (0) 0 (0) 2 (5.9)
More than 4 4 (18.1a) 0 (0) 2 (66.7) 6 (17.7)
Not reported 1 (4.6) 0 (0) 0 (0) 1 (2.9)
Total number of investigational drugs 1 drug 19 (86.4) 9 (100) 3 (100) 31 (91.2)
2 drugs 3 (13.6) 0 (0) 0 (0) 3 (8.8)
Randomization Yes 1 (4.5a) 0 (0) 0 (0) 1 (2.9)
No 0 (0) 0 (0) 1 (33.3) 1 (2.9)
Not applicable 21 (95.5) 9 (100) 2 (66.7) 32 (94.2a)
Blinding Blinding present 0 (0) 0 (0) 0 (0) 0 (0)
No blinding 22 (100) 9 (100) 3 (100) 34 (100)
Further studies recommended Yes 7 (31.8) 3 (33.3) 2 (66.7) 12 (35.4a)
No 2 (9.1) 1 (11.1) 0 (0) 3 (8.8)
Not reported 12 (54.6) 5 (55.6) 1 (33.3) 18 (52.9)
Not applicable 1 (4.5a) 0 (0) 0 (0) 1 (2.9)
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average, one in four children who enroll in pediatric phase 
II trials respond to a targeted therapy agent, while one in 63 
die from drug-related AEs. However, the response rates and 
drug-related deaths vary from study to study and depend on 
the type of malignancy. For example, in our sample of 34 
clinical trials, one study (NCT01460160) reported that 99 
patients out of 109 patients enrolled (90.8%) achieved com-
plete remission; and another study (NCT03257631) reported 
Table 2  Characteristics of patients
ECOG Eastern Cooperative Oncology Group, WHO World Health Organization
a Sex was not reported in 1 mixed malignancy, 2 solid tumor, and 3 hematological malignancy studies
b Age was not reported in 1 mixed malignancy, 3 solid tumor, and 2 hematological malignancy studies
c Other: Lansky/Karnofsky scale plus Standard Children’s Oncology Group criteria for performance status
d Percentage was calculated by subtracting the remaining % values from 100%
Characteristic Category Type of tumor Total
Solid Hematological Both
Enrolled patients, n 559 491 152 1202
Evaluated patients, n (%) 524 (93.7) 470 (95.7) 151 (99.3) 1145 (95.3)
Male, n (%)a 290 (51.9) 214 (43.6) 80 (52.6) 584 (48.6)
Median age at enrollment, n (%) 
of  studiesb, years
< 6 0 (0) 0 (0) 0 (0) 0 (0)
6.0–11.9 9 (40.9) 3 (33.3) 2 (66.7) 14 (41.2)
12.0–17.9 8 (36.4) 3 (33.3) 0 (0) 11 (32.4)
18–21 2 (9.1) 1 (11.1) 0 (0) 3 (8.8)
Performance status scale used, n 
(%) of studies
Lansky/Karnofsky scale 16 (72.7) 4 (44.4) 1 (33.3) 21 (61.8)
ECOG/WHO/Zubrod 1 (4.6) 1 (11.2d) 0 (0) 2 (5.9)
Both 4 (18.1d) 2 (22.2) 1 (33.3) 7 (20.6)
Otherc 0 (0) 0 (0) 1 (33.4d) 1 (2.9)
Not reported 1 (4.6) 2 (22.2) 0 (0) 3 (8.8)
Table 3  Response rates and toxicity in the type of malignancy subgroups
AE adverse event, CI confidence interval
a Responses of 3 studies including both types of malignancies were analyzed separately
b P value from Q test for heterogeneity comparing response rates, drug-related grade 3/4 AEs rates, and drug-related grade 5 AE rates between 
types of malignancy
c Fatal (grade 5) AEs related to treatment of 1 study including both types of malignancies were analyzed separately
Outcome Measure Type of malignancy
Solid tumors Hematological malignancies Solid and hematological
Benefit (34 clinical  trialsa) No. of studies 25 12 34a
Response rate, % (95% CI) 6.4 (3.2–9.6) 55.1 (35.9–74.3) 24.4 (14.5–34.2)
P value < 0.001b –
Drug-related fatal (grade 5) AEs 
(20 clinical  trialsc)
No. of studies 15 6 20c
Drug-related grade 5 AE rate, % 
(95% CI)
2.5 (1.1–4.0) 0.8 (0.01–1.8) 1.6 (0.6–2.5)
P value 0.1b –
Benefit (20 clinical trials where 
drug-related grade 5 AEs 
 reportedc)
No. of studies 15 6 20c
Response rate, % (95% CI) 2.2 (0.8–3.5) 36.0 (8.1–64.2) 16.0 (6.0–26.0)
P value 0.0018b –
Patients with drug-related grade 
3/4 AEs (12 clinical trials)
No. of studies 9 3 12
% of patients with drug-related 
3/4 AEs (95% CI)
49.2 (29.0–68.4) 48.3 (6.6–93.6) 49.0 (31.3–66.7)
P value 0.81b –
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ten treatment-emergent adverse events leading to death on 
53 patients enrolled (18.9%).
In our previous meta-analysis of 74 pediatric oncology, 
phase I targeted therapy studies enrolling 2264 patients, we 
reported that the pooled objective response rate for targeted 
therapy trials was: 3.5% (95% CI 2.8–4.3), while the over-
all drug-related fatal (grade 5) AE rate was 1.8% (95% CI 
1.0–2.6) [17]. The overall response rate for solid tumor trials 
was lower in targeted phase I trials (2.5%) than in phase II 
trials (6.4%). This rate was also lower in hematological stud-
ies: 22.8% vs 55.1%. In the case of a treatment-related grade 
5 AE rate for solid tumors, it was 1.7% in phase I trials vs 
2.5% in phase II trials and for hematological malignancies: 
3.2% vs 0.8%. These findings support an expectation that 
pediatric phase II trials in oncology may pose a lower risk 
and a higher probability of direct benefit for the participants 
than phase I trials [17, 36].
Despite the growing role of targeted therapy, continu-
ous innovation, and recent emphasis on precision oncology, 
we found that the overall response rate in phase II targeted 
therapy trials (24.4%) is similar to the overall response rate 
in pediatric phase II cancer chemotherapy trials (19.6%; N 
= 45). The overall fatal AE rate in targeted therapy trials 
(1.6%) was also similar to that reported with chemotherapy 
trials (1.4%) [37]. However, a larger study of 570 phase II 
single-agent studies including 32,149 patients with non-
pediatric cancers reports higher response rates for targeted 
therapy trials that adopted a personalized approach vs those 
that lacked a personalized strategy: median response 31.3% 
vs 7.5%; p < 0.0001 [38]. The median treatment-related 
death rate for the personalized therapy approach was similar 
to our result (1.5%) and slightly higher for all arms testing 
targeted agents (1.9%) [38].
Similarly to our previous study [17], we found a signifi-
cantly higher overall response rate in hematological malig-
nancies compared with solid tumors. The reasons are bio-
logical differences between these malignancies and different 
criteria of response measurement. We also found that the 
studies including three or fewer types of malignancies have 
a higher probability of benefit than the studies with four or 
more malignancies. The systematic analysis by Franshaw 
et al. published in 2019 supports this claim [39].
We did not compare the response rates between single-
drug and multiple-drug studies because the majority of tri-
als in our sample were single-drug studies. Previous stud-
ies have shown that using a combination of a few agents 
increases the likelihood of benefiting in a trial [17, 39, 40].
We did not observe higher response rates in solid tumor 
seamless clinical trials than in traditional phase II clinical 
trials. The reason may be that only a few seamless clini-
cal trials ultimately met our inclusion criteria and were 
analyzed.
Our findings should be interpreted in light of the follow-
ing limitations. First, we used broad inclusion criteria to 
analyze the overall response rate and drug-related adverse 
events in all available results of phase II trials by includ-
ing not only published articles but also abstracts and sum-
mary results posted on the ClinicalTrials.gov registry. This 
resulted in differences in the quality of outcomes reporting, 
which remains poor even in highly ranked oncology journals 
[41], and an overall serious risk of bias in the majority of 
included trials. For instance, we excluded 14 trials (41%) 
Fig. 1  Time trends in response 
rates by type of malignancy. 
Response rates were calculated 
for categories of publication 
year (2015–16, 2017–18, and 
2019–20). Error bars indicate 
standard error
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from the meta-analysis of the drug-related grade 5 AE rate 
and 22 trials (65%) from the meta-analysis of drug-related 
grade 3 and 4 AEs, mainly because these outcomes were not 
clearly reported as treatment related. As a result, our risk 
estimates may be either over-estimated or underestimated. 
Moreover, participants’ age was not reported in six trials 
(18%). Second, in 14 clinical trials, the number of drug-
related deaths was reported to be zero while ten out of the 
total 16 treatment-related deaths were reported in one study 
(NCT03257631), which significantly influenced the overall 
drug-related grade 5 AE rate. Third, the trials included in our 
analysis were heterogeneous. Generally, we observed greater 
heterogeneity in the measurement of response rate than the 
drug-related fatal AE rate, and in hematological malignancy 
studies compared with solid tumor studies. We reduced it 
by performing subgroup analyses within cancer types (solid 
tumors and hematological malignancies) according to the 
number of drugs tested in a trial, study type, and the num-
ber of malignancies included in a study. Fourth, we did not 
explore whether cancer phase II clinical trials integrating 
biomarkers as eligibility criteria have higher response rates, 
as it was observed in single-agent targeted therapy, phase I 
studies [20]. However, this limitation may determine a pos-
sible direction for future research. Fifth, objective response 
and progression-free survival are considered only surrogates 
for clinical benefit and do not necessarily translate to patient-
centered outcomes as overall survival [42–47]. In addition, 
progression-free survival or overall survival are either not or 
inconsistently reported in phase II trials. For example, in our 
sample, three out of 34 studies reported median progression-
free survival, and one study reported median overall sur-
vival. Moreover, the reported survival rates included results 
for incomparable periods of time, with a range of 3 months 
to 10 years. Finally, all such analyses are necessarily fraught 
with publication bias as trials with poor response and signifi-
cant toxicities may never be published while positive studies 
are rapidly published.
5  Conclusions
Our systematic review of phase II trials testing targeted 
therapy agents in pediatric oncology demonstrated risks and 
benefits, the acceptability of which must be judged by the 
physician and patient (and patient’s guardians) on a case-
by-case basis. Our data provide an empirical basis to cur-
rent discussion regarding the risk/benefit profile in pediat-
ric oncology research. It also contributes to communication 
about the benefits and burdens in pediatric phase II cancer 
trials to participants and their guardians.
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